Hizbillah Yazid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hizbillah Yazid has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Arif Zulkarnain
Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Orthopedics and Traumatology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
2 shared publications - Tri Wahyu Martanto
Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Indonesia
2 shared publications - Agus Kresnadi
Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia
1 shared publication - Dwikora Novembri Utomo
Department of Orthopaedics and Traumatology, Faculty of Medicine, Airlangga University, Surabaya 60286, Indonesia
1 shared publication - I Putu Alit Pawana
Department of Physical Medicine and Rehabilitation, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, East Java, 60286
1 shared publication Komang Agung Irianto
Staff of Orthopaedic and Traumatology Department, Faculty of Medicine, Universitas Airlangga, Dr Soetomo General Hospital, Surabaya
1 shared publication
Latest Publications
- Open Access
- 8 May 2026
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Early outcomes of closed reduction followed by double spica casting and gait assessment in children aged 18–48 months with developmental dysplasia of the hip
- 8 May 2026
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Open AccessEarly outcomes of closed reduction followed by double spica casting and gait assessment in children aged 18–48 months with developmental dysplasia of the hip
- Open Access
- 4 April 2024
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 4, 894
The Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review
Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and susceptibility to fractures. Management of OI focuses on minimizing fractures and improving bone strength. Denosumab and bisphosphonates have emerged as potential therapeutic agents in OI management due to their ability to modulate bone turnover. This literature review aims to explore the role of denosumab and bisphosphonates in the treatment of OI, highlighting their mechanisms of action, efficacy, and safety profiles. A comprehensive search was conducted across various databases, to identify relevant studies investigating the use of denosumab and bisphosphonates in OI management. The review discusses the molecular pathways underlying the pathogenesis of OI and how denosumab and bisphosphonates intervene in these pathways to improve bone quality. Furthermore, the review summarizes the findings from clinical trials and observational studies evaluating the effectiveness of denosumab and bisphosphonates in reducing fracture rates, improving bone mineral density, parathyroid hormone changes, calcium and phosphate quantity, and also enhancing functional outcomes in patients with OI. Additionally, considerations regarding optimal dosing, timing of initiation, and potential adverse effects of denosumab and bisphosphonates in individuals with OI are discussed. The synthesis of existing evidence underscores the promising role of denosumab and bisphosphonates as adjunctive therapies in the management of OI, although further research is warranted to elucidate their long-term efficacy and safety profiles in this patient population
- 4 April 2024
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 4, 894
Open AccessThe Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review
Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and susceptibility to fractures. Management of OI focuses on minimizing fractures and improving bone strength. Denosumab and bisphosphonates have emerged as potential therapeutic agents in OI management due to their ability to modulate bone turnover. This literature review aims to explore the role of denosumab and bisphosphonates in the treatment of OI, highlighting their mechanisms of action, efficacy, and safety profiles. A comprehensive search was conducted across various databases, to identify relevant studies investigating the use of denosumab and bisphosphonates in OI management. The review discusses the molecular pathways underlying the pathogenesis of OI and how denosumab and bisphosphonates intervene in these pathways to improve bone quality. Furthermore, the review summarizes the findings from clinical trials and observational studies evaluating the effectiveness of denosumab and bisphosphonates in reducing fracture rates, improving bone mineral density, parathyroid hormone changes, calcium and phosphate quantity, and also enhancing functional outcomes in patients with OI. Additionally, considerations regarding optimal dosing, timing of initiation, and potential adverse effects of denosumab and bisphosphonates in individuals with OI are discussed. The synthesis of existing evidence underscores the promising role of denosumab and bisphosphonates as adjunctive therapies in the management of OI, although further research is warranted to elucidate their long-term efficacy and safety profiles in this patient population
- Open Access
- 9 December 2019
- Published by Universitas Airlangga in (JOINTS) Journal Orthopaedi and Traumatology Surabaya
- Vol. 8 (1) , 47-58
CONGENITAL SCOLIOSIS: AN ARTICLE REVIEW
Background: Congenital Scoliosis (CS) defined as vertebral lateral deviation which forms during the intrauterine embryonic phase, carrying incidence between 0,5-1 per 1000 births. Mortality rate increases in untreated case, especially due to pulmonary problem (40%).Contents: CS can range from hemivertebrae (HV) which may be single or multiple, vertebral bar with or without HV, block vertebrae, wedge shaped or butterfly vertebrae. The risk factors for progression include: type of defect, site of defect, and the patient’s age. Plain radiographs remain standard diagnosis. MRI evaluation should be considered. The goal of managing CS is to obtain a balanced trunk and spine while maintaining as much normal spinal growth as possible and preventing neural deficit. Non-operative management is including observation, brace, and traction. The operative procedures are broadly divided into (a) those preventing further deformity: in situ fusion, convex hemiepiphysiodesis, and HV excision, (b) those that correct the present deformity: hemiepiphyseodesis & hemiarthrodesis, single & dual growing rods, HV excision, and reconstructive osteotomy.Conclusion: The treatment of CS remains one of the more challenging aspects of pediatric orthopaedic surgery. Operative treatment should be reserved for patients whom non-operative management didn’t meet the criteria or failed.
- 9 December 2019
- Published by Universitas Airlangga in (JOINTS) Journal Orthopaedi and Traumatology Surabaya
- Vol. 8 (1) , 47-58
Open AccessCONGENITAL SCOLIOSIS: AN ARTICLE REVIEW
Background: Congenital Scoliosis (CS) defined as vertebral lateral deviation which forms during the intrauterine embryonic phase, carrying incidence between 0,5-1 per 1000 births. Mortality rate increases in untreated case, especially due to pulmonary problem (40%).Contents: CS can range from hemivertebrae (HV) which may be single or multiple, vertebral bar with or without HV, block vertebrae, wedge shaped or butterfly vertebrae. The risk factors for progression include: type of defect, site of defect, and the patient’s age. Plain radiographs remain standard diagnosis. MRI evaluation should be considered. The goal of managing CS is to obtain a balanced trunk and spine while maintaining as much normal spinal growth as possible and preventing neural deficit. Non-operative management is including observation, brace, and traction. The operative procedures are broadly divided into (a) those preventing further deformity: in situ fusion, convex hemiepiphysiodesis, and HV excision, (b) those that correct the present deformity: hemiepiphyseodesis & hemiarthrodesis, single & dual growing rods, HV excision, and reconstructive osteotomy.Conclusion: The treatment of CS remains one of the more challenging aspects of pediatric orthopaedic surgery. Operative treatment should be reserved for patients whom non-operative management didn’t meet the criteria or failed.